Johnson & Johnson reported strong fiscal 2013 results with significant growth in pharmaceuticals and successful integration of acquisitions like Synthes. Despite some headwinds such as currency fluctuations and pricing pressures in Europe, management remains optimistic about continued growth and strategic initiatives. The positive earnings and steady guidance are likely to support a modest short-term uplift in the stock price.

[1]